Patents by Inventor Amy S. Ripka

Amy S. Ripka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF THE VE-PTP PHOSPHATASE PROTECTS THE KIDNEY FROM ISCHEMIA-REPERFUSION INJURY
    Publication number: 20220372169
    Abstract: This disclosure relates to inhibition of the VE-PTP phosphatase to protect the kidney from ischemia-reperfusion injury. This disclosure also relates to conditional knockout of VE-PTP to protect or improve the renal function in ischemia-reperfusion injury. This disclosure identifies VE-PTP as a promising therapeutic target for renal protection in ischemia-reperfusion injury and proposes using small molecule VE-PTP inhibitor to bestow protection in the context of acute kidney injury.
    Type: Application
    Filed: October 30, 2020
    Publication date: November 24, 2022
    Inventors: Susan E. QUAGGIN, Michael C. RYCZKO, Amy S. RIPKA
  • N-biphenylmethylbenzimidazole modulators of PPARG
    Patent number: 9309227
    Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: April 12, 2016
    Assignees: The Scripps Research Institute, Ember Therapeutics, Inc.
    Inventors: Theodore Mark Kamenecka, Patrick R. Griffin, Amy S. Ripka, Jeffrey O. Saunders
  • Compounds of modulating TRPV3 function
    Patent number: 9181219
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 10, 2015
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Magdalene M. Moran, Jayhong A. Chong, Christopher Fanger, Amy S. Ripka, Glenn R. Larsen, Xiaoguang Zhen, Dennis John Underwood, Manfred Weigele
  • N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG
    Publication number: 20150141464
    Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5 -mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 21, 2015
    Inventors: Amy S. RIPKA, Jeffrey O. SAUNDERS
  • N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG
    Publication number: 20140288090
    Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
    Type: Application
    Filed: November 20, 2012
    Publication date: September 25, 2014
    Inventors: Theodore Mark Kamenecka, Patrick R. Griffin, Amy S. Ripka, Jeffrey O. Saunders
  • N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG
    Publication number: 20140249196
    Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
    Type: Application
    Filed: November 20, 2012
    Publication date: September 4, 2014
    Inventors: Theodore Mark Kamenecka, Patrick R. Griffin, Amy S. Ripka, Jeffrey O. Saunders
  • Compounds of Modulating TRPV3 Function
    Publication number: 20140011840
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 9, 2014
    Applicant: Hydra Biosciences, Inc.
    Inventors: Magadalene M. Moran, Jayhong A. Chong, Christopher Fanger, Amy S. Ripka, Glenn R. Larsen, Xiaoguang Zhen, Dennis John Underwood, Manfred Weigele
  • Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function
    Patent number: 8552009
    Abstract: The present application relates to compounds of Formula I as defined herein, and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 8, 2013
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy S. Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer